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Sterol regulatory element-binding proteins (SREBPs)
are major transcription factors activating the expres-
sion of genes involved in biosynthesis of cholesterol,
fatty acid and triglyceride. In this study, we identified
a small molecule, betulin, that specifically inhibited
the maturation of SREBP by inducing interaction of
SREBP cleavage activating protein (SCAP) and Insig.
Inhibition of SREBP by betulin decreased the biosyn-
thesis of cholesterol and fatty acid. In vivo, betulin
ameliorated diet-induced obesity, decreased the
lipid contents in serum and tissues, and increased
insulin sensitivity. Furthermore, betulin reduced the
size and improved the stability of atherosclerotic pla-
ques. Our study demonstrates that inhibition SREBP
pathway can be employed as a therapeutic strategy
to treat metabolic diseases including type II diabetes
and atherosclerosis. Betulin, which is abundant in
birch bark, could be a leading compound for devel-
opment of drugs for hyperlipidemia.
INTRODUCTION
Hyperlipidemia is closely related to metabolic diseases, such as
atherosclerosis and type II diabetes, which are becoming world-
wide problems (Le, 2006). Atherosclerosis is the most common
cause of coronary heart disease, stroke, and cardiovascular
death. Hypercholesterolemia, typically associated with
increased levels of serum cholesterol, is one of the major risk
factors for atherosclerosis (Steinberg, 2002). Hypertriglyceride-
mia, characterized by high levels of triglyceride and fatty acid
in blood, contributes to the development of insulin resistance
and type II diabetes (Brunzell and Hokanson, 1999).
In mammals, the biosynthesis of cholesterol, fatty acid, and
triglyceride are tightly regulated by a family of transcription
factors called sterol regulatory element-binding proteins
(SREBPs) (Goldstein et al., 2006). The precursor of SREBP
(pre-SREBP) is synthesized as an endoplasmic reticulum (ER)44 Cell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc.membrane-bound protein. Its activation requires the cleavage
of precursor to release the nuclear form and this process is
regulated by sterol. When sterol is low, SCAP escorts SREBP
from ER to Golgi apparatus, where SREBP is sequentially
cleaved by two proteases: site-1 protease (S1P) and site-2
protease (S2P). Therefore, the nuclear form of SREBP (n-
SREBP) is released and transported to nucleus to activate
gene expression. When cellular sterol level is high, cholesterol
or oxysterols (i.e., 25-hydroxycholesterol [25-HC]) stimulate
the association between SCAP and Insig, causing the ER reten-
tion of SCAP-SREBP complex and thereby reducing n-SREBP
and decreasing the expression of genes involved in lipid
metabolism.
There are three forms of SREBP in mammals: SREBP-1a, -1c
and -2 (Horton et al., 2002). Although they undergo similar
proteolytic activation and share some target genes, SREBP-1a
and -1c mainly stimulate fatty acid synthesis, whereas SREBP-2
acts primarily on the cholesterol biosynthetic genes and LDL
receptor (LDLR) gene. Liver-specific knockout of SCAP or S1P
in mice blocks SREBP cleavage and leads to the decrease of
lipid synthesis and reduced plasma cholesterol and triglyceride
levels, indicating that SREBP inhibition in patients with hyperlip-
idemia can provide beneficial effects (Yang et al., 2001; Matsuda
et al., 2001).
LXR is another sterol regulated transcription factor whose
native activators are oxysterols such as 24, 25-expoxycholes-
terol, and 25-HC (Repa and Mangelsdorf, 2000). Activation of
LXR stimulates the expression of a variety of genes, including
ABCA1, ABCG5/8, and Cyp7a1, that mediate the efflux and
clearance of cholesterol (Venkateswaran et al., 2000; Repa
et al., 2002; Peet et al., 1998). However, LXR also upregulates
the expression of SREBP-1c (Repa et al., 2000), the predominant
isoform of SREBP-1 in liver. Therefore, although activation of
LXR by pharmacological ligands reduces serum cholesterol level
and protects against atherosclerosis (Joseph et al., 2002; Tera-
saka et al., 2003), it also leads to hepatic steatosis and hypertri-
glyceridemia due to the induction of fatty acid synthesis through
activation of SREBP-1c (Schultz et al., 2000). For this reason, the
current well-known inhibitors of SREBP processing, including
24-HC, 25-HC, and 27-HC, may not be clinically used to treat
hyperlipidemia since they also activate LXR (Repa and
Figure 1. Betulin Specifically Inhibits SREBP
Processing
(A) Betulin inhibits the cleavage of endogenous SREBP-1
and -2. Rat hepatocytes CRL-1601 were depleted of
sterols by incubating in medium A containing 5% LPDS,
10 mM compactin, and 10 mM mevalonate for 16 hr at
37C. Cells were then switched to medium A containing
5% LPDS, 10 mM compactin, and 10 mM mevalonate
and indicated concentration of 25-HC or betulin. After
incubation for 6 hr, cells were harvested and lysed to
prepare nuclear and membrane fractions. Immunoblots
were performed with anti-SREBP-1 or anti-SREBP-2
antibodies.
(B) Betulin does not stimulate the degradation of trans-
fected HMGCR. After transfection of the indicated plas-
mids, CHO-7 cells were depleted of sterols by incubation
in medium B containing 5% LPDS, 10 mM compactin, and
10 mM mevalonate for 16 hr at 37C. Cells were then
switched to medium B containing 5% LPDS, 10 mM
compactin, 10 mM mevalonate, and increasing concen-
trations of 25-HC or betulin for 5 hr. Membrane fraction
was prepared, and immunoblots were carried out with
anti-T7 (against HMGCR) or anti-Myc (against Insig-1)
antibodies.
(C) Betulin inhibits the cleavage of transfected SREBP-2.
SCAP-deficient CHO cells (SRD-13A) were transfected
with indicated plasmids and depleted of sterols as
described in Figure 1B. The cells were then treated with
25-HC or betulin for 6 hr in medium B containing 5%
LPDS, 10 mM compactin, and 10 mMmevalonate. Nuclear
and membrane fractions were prepared and subjected to
immunoblot with anti-Flag (against SREBP-2), anti-SCAP,
or anti-Myc (against Insig-1) antibodies.
(D) Betulin stimulates the interaction between transfected SCAP and Insig-1. SRD-13A cells were transfected, depleted of sterols, and treated with 25-HC or
betulin for 6 hr as described in Figure 1C. The lysates were subjected to immunoprecipitation with anti-Myc-agarose to pull down Insig-1. Immunoblots were
performed with anti-SCAP or anti-Myc (against Insig-1) antibodies.
See also Figure S1.
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inhibit the SREBP pathway without activating LXR should
decrease the biosynthesis of both cholesterol and fatty acid
and thereby be useful in the treatment of atherosclerosis and
type II diabetes.
In this study, through a chemical screening, we identified the
small molecule betulin as a specific inhibitor of SREBP
pathway. Betulin bound SCAP and stimulated the interaction
between SCAP and Insig, blocked the maturation of SREBPs,
and downregulated the genes for cholesterol and fatty acid
biosynthesis. Betulin treatment decreased the lipid levels in
serum and tissues and increased insulin sensitivity in
western-type diet ingested mice. Furthermore, betulin applica-
tion on an atherosclerosis disease model, LDLR-knockout
mice, showed that it reduced the size and improved the
stability of atherosclerotic plaques.
RESULTS
Identification of Betulin as a Specific Inhibitor of SREBP
Processing
The nuclear form of SREBP binds to sterol regulatory element
(SRE) and enhances the target gene expression, through
which the lipid biosynthesis is increased (Wang et al., 1993).
To screen for small-molecule compounds that inhibit SREBP,Cwe constructed a luciferase reporter driven by a SRE-containing
promoter and generated a cell line stably expressing this reporter
from human hepatoma cell line Huh-7 (named Huh-7/SRE-Luc)
(Figure S1A available online). This cell was then incubated with
compounds followed by luciferase activity assay. As a positive
control, 25-HC dramatically inhibited the reporter. Interestingly,
betulin [lup-20(29)-ene-3b, 28-diol] efficiently lowered the lucif-
erase activity (Figure S1B). Betulin is an abundant naturally
occurring pentacyclic triterpene (Figure S1C) that can be easily
isolated (up to 30% dry weight) from the birch bark by extraction
(Alakurtti et al., 2006).
Next, the effect and specificity of betulin on SREBP pro-
cessing were directly examined and compared with those of
25-HC. 25-HC had three major effects: decreasing n-SREBP-2
by inhibiting SREBP-2 cleavage (Figure 1A), activating LXR that
in turn upregulates the transcription of SREBP-1 and causes
the increase of n-SREBP-1 (Figure 1A), and promoting the
degradation of HMG-CoA reductase (HMGCR) (DeBose-Boyd,
2008), a rate-limiting enzyme in cholesterol biosynthesis
(Figure 1B). On the other hand, betulin potently decreased
both endogenous n-SREBP-1 and n-SREBP-2 (Figure 1A), sug-
gesting that it inhibits SREBP processing without activating
LXR. Meanwhile, betulin did not promote the degradation of
transfected HMGCR (Figure 1B). Consistently, betulin
completely blocked the cleavage of transfected SREBP-2 inell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc. 45
Figure 2. Betulin Binds to SCAP
(A) Structure of a betulin-derived photoaffinity
probe (compound 1) and schematic representa-
tion of the in vitro photoaffinity labeling reaction.
(B) Compound 1 inhibits the processing of
SREBP-2 just like its parent compound, betulin,
does. CHO-7 cells were depleted of sterols by
incubating in medium B containing 5% LPDS,
10 mM compactin, and 10 mM mevalonate for
16 hr at 37C. Cells were then switched to medium
B containing 5% LPDS, 10 mM compactin, and the
indicated concentrations of betulin or compound 1
for 6 hr. Cells were harvested, and the membrane
fraction and nuclear extract were prepared and
subjected to immunoblot with IgG-7D4 (anti-
SREBP-2).
(C) Compound 1 binds to SCAP, which can be
competed off by betulin. CHO-7 cells were
depleted of sterols by incubation in medium B
containing 5% LPDS, 10 mM compactin, and
10 mM mevalonate for 16 hr at 37C. Membrane
fractions were prepared and incubated with the
indicated concentrations of compound 1 in the
absence or presence of 100 mM of betulin at 4C
for 3 hr and were then exposed to UV 365 nm for
1 hr. After UV irradiation, a biotin tag was attached
by the click chemistry at room temperature for
1 hr. Then the membrane pellets were homoge-
nized and incubated with avidin-conjugated
agarose at 4C for 12 hr to pull down betulin-tar-
geting protein. Immunoblots were performed
with anti-SCAP (IgG-9D5) or anti-transferrin
receptor antibodies.
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specifically inhibits the SREBP processing but does not
activate LXR or accelerate HMGCR degradation. Furthermore,
betulin stimulated the interaction between SCAP and Insig-1
in coimmunoprecipitation experiments (Figure 1D, lanes 4 and
5), which provides an action mechanism of betulin.
To further test whether betulin functions by binding to SCAP,
a betulin-derived probe was synthesized and named as
compound 1 (Figure 2A). Compound 1 contains a photoreac-
tive group and an azido-acetyl group that can link to biotin
alkyne through click chemistry. Similar as betulin, compound
1 could inhibit the processing of SREBP-2 (Figure 2B).
Compound 1 was incubated with the membrane fractions
from cholesterol-deleted CHO cells followed by exposure to
UV to activate the crosslinking. After ultraviolet (UV) irradiation,
a biotin tag was attached by click chemistry. Then the
membrane pellets were homogenized and incubated with
avidin-conjugated agarose to pull down betulin binding
proteins. As shown in Figure 2C, SCAP was precepitated in
the precence of 1 and 3 mM of compound 1 and the binding46 Cell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc.can be competed off by high concentra-
tion of betulin, which indicates that
betulin physically interacts with SCAP.
As a negative control, transferrin
receptor was barely precipitated with
compound 1 and betulin competition
showed no effect (Figure 2C, bottom
panel). Totether, these results show that SCAP may bind to
betulin and is its target.
Betulin Downregulates SREBP Target Genes and
Decreases Cellular Lipid Levels
Since SREBP-2 is a direct target of itself (Sato et al., 1996),
betulin downregulated its expression by 40% (Figure 3A).
Consistent with the notion that SREBP-2 is a master transcrip-
tion factor for cholesterol biosynthesis, the ten measured genes
in cholesterol synthetic pathway, such as HMGCR, HMG-CoA
synthase (HMGCS), and squalene epoxidase (SE), were all
reduced by betulin treatment (Figure 3A). Similarly, all of the
nine genes involved in fatty acid and triglyceride synthesis,
such as SREBP-1c, fatty acid synthase (FAS), and acetyl-Co
A carboxylase alpha (ACC), were significantly downregulated
by betulin (Figure 3B). Consistent with earlier observations (Fig-
ure 1A), LXR target genes, including ABCG5 and ABCG8, were
not affected by betulin (Figure 3C).
Consistant with the changes of gene expression, betulin treat-
ment significantly reduced the de novo synthesis of both
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Betulin Inhibits SREBP Processingcholesterol and fatty acid in a concentration-dependent manner
(Figures 3D–3E). Furthermore, betulin decreased the steady-
state levels of cellular cholesterol (Figure 3F) and neutral lipids
(mainly cholesterol ester and triglyceride) (Figure 3G). Taken
together, our data suggest that betulin inhibits SREBP process-
ing and downregulates cholesterol and fatty acid biosynthesis,
thereby decreasing cellular lipid levels. Interestingly, lovastatin
dramatically decreased cholesterol synthesis (Figure 3D), but it
also modestly increased fatty acid biosynthesis (Figure 3E).
It is likely because that lovastatin is an inhibitor of HMGCR that
can block cholesterol synthesis, in turn stimulate SREBP activa-
tion, and thereby increase fatty acid synthesis.
Betulin Ameliorates Diet-InducedObesity and Increases
Energy Expenditure in Mice
Next, we investigated the effect of betulin in vivo. Lovastatin is
an inhibitor of HMGCR with well-accepted beneficial effects,
and betulin was compared with it. The C57BL/6J mice on
western-type diet (WD) were treated with vehicle (saline), lova-
statin (30 mg/kg/day), or betulin (15 or 30 mg/kg/day) for
6 weeks. During the treatment, no obvious toxicity of betulin
or lovastatin was observed and the different groups of mice
showed similar food intake (Figure 4A). Interestingly, although
the mice fed with WD plus betulin or lovastatin at 30 mg/kg/
day were still heavier than the chow diet-fed mice, they showed
less body-weight gain than WD-fed mice, suggesting that
betulin and lovastatin can prevent diet-induced obesity (DIO)
at this dosage (Figure 4B). The effect of lovastatin on body
weight is consistent with previous report (Otto et al., 1995).
Meanwhile, nuclear magnetic resonance analysis showed that
the fat/lean or fat/body-weight ratios dropped by 35%–40%
in the same dosage of betulin and lovastatin-treated mice
(Figure S2).
To understand the anti-DIO effect of betulin and statin, we
further analyzed the lipid absorption, physical activity and
energy expenditure. In lovastatin-treated mice, although the
respiratory quotient (RQ) was augmented, suggesting a switch
to whole-body utilization of glucose and protein for energy
production over lipid oxidation, the oxygen consumption and
total energy expenditure were still similar to WD-fed mice
(Figures 4F–4H). On the other hand, the fecal cholesterol and
triglyceride (TG) were significantly increased in mice fed with
lovastatin (Figures 4C and 4D), indicating that lovastatin
decreased lipid absorption or increased lipid excretion to antag-
onize DIO. This observation is consistent with the previous
reports (Nielsen et al., 1993; Ishida et al., 1990; Jeon et al.,
2004; Otto et al., 1995). On the other hand, betulin had no effect
on lipid absorption/excretion (Figures 4C and 4D). Although the
physical activities of every group of micewere similar (Figure 4E),
the RQ of the mice received betulin was elevated (Figure 4F) and
their oxygen consumption and energy expenditure were also
increased (Figures 4G and 4H), which may contribute to their
decreased body-weight gain. Meanwhile, the mice received
30 mg/kg/day of betulin showed higher body temperature
when exposed to cold (Figure 4I). Further Q-PCR analysis
showed that UCP-1 and UCP-2, two key thermogenic genes
in brown adipocyte tissue (BAT), were elevated in betulin-
treated mice (Figure 4J). This observation is consistent with
the report that UCP-1 was dramatically decreased in BAT ofCthe n-SREBP-1c transgenic mice (Shimomura et al., 1998).
How SREBP regulates UCPs in BAT is still unknown and may
be pursued in the future.
In summary, these data show that lovastatin may prevent DIO,
at least partly, by decreasing lipid absorption/increasing excre-
tion, whereas betulin ameliorates DIO through increasing energy
expenditure. Similar phenomena were observed on high-fat diet
(HF)-fed mice (Figures S3A–S3C).
Betulin Improves the Lipid Parameters in Blood, Liver,
and Adipose Tissues in Mice
The lipid levels in blood and other tissues were measured and
shown in Figure 5. The serum total cholesterol (TC) and triglyc-
eride (TG) levels in lovastatin and betulin treated mice were
significantly lower than those of the vehicle-treated mice
(Figures 5A and 5B). Notably, betulin decreased the content
of LDL cholesterol (LDL-c) and increased HDL cholesterol
(HDL-c) similar as lovastatin (Figures 5C and 5D). Interestingly,
although both betulin and lovastatin decreased the TC level in
liver, only betulin significantly reduced the TG in liver (Figures
5E and 5F).
Histological analysis showed that betulin reduced the cell size
of both white adipocyte tissue (WAT) and brown adipocyte tissue
(BAT), while lovastatin only reduced the size of brown adipocytes
(Figure 5G). Oil red O section staining showed that the livers of
lovastatin or betulin-treated mice contained lower lipid accumu-
lation compared with the livers of vehicle-treated mice fed on
WD (Figure 5G). This is consistent with the previous data that
lovastatin and betulin decreased the hepatic lipid contents
(Figures 5E and 5F).
To further investigate whether betulin causes these beneficial
in vivo effects through modulating SCAP-SREBP pathway, we
utilized adenovirus-mediated RNA interference (RNAi) to reduce
the expression of SCAP in mice liver. Gene expression and blood
lipid levels were then measured. SCAP short hairpin RNA
(shRNA) reduced the expression of SCAP in mice liver by more
than 50% (Figure S4A). Consistent with early data, betulin can
efficiently decrease the messenger RNA (mRNA) of SREBP-2,
HMGCS, and squalene synthase (SS) in mice liver receiving
control shRNA (Figure S4A). SCAP knockdown itself also
dramatically reduced the expression of these genes (Figure S4A),
since SCAP depletion causes inhibition of SREBP. Importantly,
betulin treatment in mice receiving SCAP shRNA had no further
effect (Figure S4A). Betulin decreased blood TC, TG, and LDL-c
and increased HDL-c in control shRNA groups (Figures S4B–
S4E). However, it had no effect in SCAP knockdown groups
(Figures S4B–S4E). Together, these results indicate that the
in vivo effects of betulin aremostly ascribed to its activity in inhib-
iting SREBP processing.
Betulin Improves Insulin Resistance in Mice
Since betulin decreases the lipid levels in both serum and
tissues, we next investigated whether betulin improves insulin
resistance in vivo. The WD-fed mice exhibited impaired glucose
and insulin tolerance compared with mice on chow diet. Betulin
or lovastatin treatment of WD-fed mice significantly improved
glucose tolerance and insulin resistance (Figures 6A–6D).
Furthermore, the elevated fasting blood glucose and insulin in
WD-fed mice were significantly reduced by betulinell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc. 47
Figure 3. Betulin Inhibits the Biosynthesis of Cholesterol and Fatty Acid by Decreasing SREBP Target Genes
(A–C) CRL-1601 cells were depleted of sterols as described in Figure 1A. The cells were then incubated inmedium A containing 5%LPDS, 10 mMcompactin, and
10 mMmevalonate in the absence or presence of 3 mg/ml betulin for 6 hr. Then the cells were lyased in Trizol reagents, andRNA sampleswere extracted according
to themanufactor’s protocol. The expression of multiple geneswas analyzed by reverse transcription followed by quantitative-PCR (Q-PCR). Error bars represent
standard deviations. The difference between control and betulin-treated samples was statistically analyzed with the Student’s t test. *p < 0.05, **p < 0.01.
(D and E) Betulin inhibits the de novo synthesis of cholesterol and fatty acid. CRL-1601 cells were incubated in 10% dilipid-FCS, 1 mM lovastatin, and 50 mM
mevalonate supplemented with increasing concentrations of betulin or 1 mM of lovastatin for 16 hr. [14C]acetate (12 mCi/60 mm dish) was directly added into
Cell Metabolism
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Betulin Inhibits SREBP Processingadministration, but not by lovastatin (Figures 6E and 6F). Similar
beneficial effects of betulin were observed in HF-fed mice
(Figures S3D–S3G). Collectively, these data demonstrate that
betulin improves insulin resistance in mice.Betulin Regulates the Expression of Metabolic Genes
In Vivo
The beneficial effects of betulin on metabolic parameters were
reflected by its effects on gene expression in liver and WAT of
mice. Betulin inhibited SREBP processing in mice liver as it
did in cultured cells (Figure S5). As SREBP-2 was transcription-
ally regulated by itself, betulin treatment reduced the hepatic
SREBP-2 mRNA by 30% (Figure S6A). Consequently, the
mRNA levels of genes involved in cholesterol biosynthesis,
including HMGCS, HMGCR, and SS, were reduced by 31%–
65% in liver of betulin-treated mice (Figure S6A). For genes in
fatty acid metabolism, betulin significantly decreased the
mRNA of SREBP-1c (32%) and its target genes, including
FAS (39%) and SCD-1 (20%). On the other hand, the levels
of malic enzyme and PPARa were increased by 59% and 31%
(Figure S6B), suggesting that betulin may reduce fatty acid
synthesis and accelerate lipolysis (Duval et al., 2007). The
mRNA of hepatic lipase (HL) and ApoE were also slightly
increased by betulin (Figure S6C). The overall trend is similar to
that in lovastatin-treated mice, indicating that these changes
may contribute to their beneficial effect on blood lipid contents
(Brown and Rader, 2007; van Dijk et al., 1999). For genes in
carbohydrate metabolism, betulin significantly increased the
G-6-PD mRNA without altering the expression of PEPCK,
IRS-1, IRS-2, or glucokinase (Figure S6D). Although both
HMGCR and LDLR are target genes of SREBP, betulin signifi-
cantly downregulated HMGCR but not LDLR (Figures S5 and
S6A), suggesting that there might be compensatory regulation
for LDLR in vivo.
WAT plays a very important role in energymetabolism, and be-
tulin dramatically enhanced the expression of adiponectin, LPL,
and PPAR-g in WAT (Figure S6E). These genes are involved in
a variety of biological functions, and their increased expression
has antidiabetic and anti-inflammatory effects (Havel, 2002;
Brown and Rader, 2007; Tontonoz and Spiegelman, 2008).
Meanwhile, the expression of FAS, SCD-1, and HMGCR was
decreased and UCP-2 was increased in WAT of betulin-treated
mice (Figure S6E), suggesting that lipid synthesis dropped and
fatty acid oxidation was enhanced after betulin treatment. This
is consistent with our observation that betulin reduced the cell
size of WAT (Figure 5G). All together, these data indicate that be-
tulin regulates SREBP target genes and metabolism-related
genes in liver and WAT, which may directly contribute to the
lower lipid level and enhanced insulin sensitivity.the medium and incubated for additional 2 hr. Cholesterol (D) and fatty acid (E) we
were visualized by phosphoimager. Densitometric quantification is shown at the
(F) Betulin decreases the cellular cholesterol level. CRL-1601 cells were incubate
500 mM sodiummevalonate, and the indicated concentrations of betulin for 12 hr.
terol. Quantification of cellular cholesterol is shown. Error bars represent the stan
post test). *p < 0.05, **p < 0.01 versus control.
(G) Betulin decreases the cellular neutral lipid level. CRL-1601 cells were treated as
ically recognizes neutral lipids. Quantification of the cellular neutral lipids is show
with one-way ANOVA (Donnett post test). *p < 0.05, ***p < 0.001 versus control.
CBetulin Decreases the Atherosclerosis Development
The effect of betulin on atherosclerotic lesion formation was
explored with LDLR-knockout mice (Ishibashi et al., 1993).
The LDLR-deficient mice were challenged with WD supple-
mented with vehicle (saline), lovastatin (30mg/kg/day), or betulin
(30 mg/kg/day) for 14 weeks. Different groups of mice showed
similar food intake and body weight (Figures 7A–7B). SREBP-1c
and SREBP-2 were decreased, and the lipid synthesis genes,
including HMGCS, HMGCR, and FAS, were downregulated in
liver of betulin-treated mice (Figure 7C). However, HMGCR and
FAS were upregulated by lovastatin (Figure 7C). Betulin dramat-
ically decreased TC, TG, and LDL-c and increased HDL-c in
blood (Figures 7D–7G). Lovastatin had the similar effects except
that it didn’t reduce TG (Figures 7D–7G). The number and size of
aortic plaques were significantly lower in lovastatin or betulin-
treated mice compared with vehicle-treated mice (Figures 7H
and 7I). Particularly, lesion areas in the aortic arch (Figure 7J)
and thoracic aorta (Figure 7K) were significantly smaller.
In another cohort of mice, quantification of the lesion areas in
cross-sections of aortic sinus showed that betulin treatment
decreased the lesion area significantly compared to vehicle
treatment (Figure S7A). Besides the areas of atherosclerotic
lesions, we also measure the stability of the plaques using
macrophage marker MOMA-2 and smooth muscle cell marker
SMC-actin (Madan and Amar, 2008). Betulin-treated mice had
features of enhanced plaque stability compared with vehicle-
treated mice, evidenced by reduced accumulation of macro-
phage by 55% (MOMA2-positive area, Figure S7B) and
increased SMCs content by 21% (SMC-actin-positive area, Fig-
ure S7C). Data above show that betulin reduces atherosclerosis
lesion formation and stabilizes atherosclerotic plaques in the
aortic root in WD-fed LDLR-knockout mice.DISCUSSION
SREBP is a major transcription factor that controls the biosyn-
thesis of cholesterol, fatty acid, and triglyceride (Goldstein
et al., 2006). In this report, we developed a cell-based assay
for SREBP pathway and identified a small-molecule inhibitor of
SREBP, betulin, by compound screening (Figure S1A). Betulin
inhibits SREBP by binding SCAP and promoting the interaction
between SCAP and Insig (Figures 2 and 1), which leads to the
ER-retention of SREBP. Betulin downregulates the genes in
cholesterol and fatty acid biosynthesis and decreases the
content of cellular lipids (Figure 3). In DIO mice, betulin
decreases the cholesterol and TG levels and increases insulin
sensitivity (Figures 5 and 6 and Figure S3). Furthermore, it
prevents atherosclerosis in LDLR-knockout mice (Figure 7 and
Figure S7). As a SREBP inhibitor, betulin shows a multitude ofre extracted and resolved by thin-layer chromatography. Radioactive products
bottom of each panel.
d in medium A for 8 hr and then incubated in medium A containing 5% LPDS,
Then cells were fixed and stained with filipin that specifically binds free choles-
dard deviation. Statistical analyses were done with one-way ANOVA (Donnett
in Figure 2F. Then the cells were fixed and stainedwith Nile-Red, which specif-
n. Error bars represent the standard deviation. Statistical analyses were done
ell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc. 49
Figure 4. Effects of Betulin on Body Weight, Fecal Lipid, and Energy Expenditure in Mice
Male C57BL/6J mice at 6 weeks of age were randomly grouped (six to nine per group). Mice were allowed ad libitum access to water and different types of diets.
Vehicle, lovastatin (30 mg/kg/day), or betulin (15 or 30 mg/kg/day) was administrated to mice by gastric irrigation once daily. After 6 week treatment, the mice
were place into metabolic chambers to measure oxygen consumption, CO2 production, physical activity, etc. Feces were collected to measure fecal cholesterol
and triglyceride. The mice were finally sacrificed and subjected to various analyses as indicated below. WD, western-type diet (normal chow supplemented with
1.25% cholesterol, 20% fat and 0.5% cholic acid, w/w); L, lovastatin; B, betulin.
(A) Food intake during the 6 week experiments.
(B) Body weight per mouse during the 6 week experiments. Error bars represent the standard deviation. Statistical analyses were done with repeated-measures
two-way ANOVA (Bonferroni post test). *p < 0.05, **p < 0.01 WD+B versus WD, WD+L versus WD.
(C) Effect of lovastatin and betulin on fecal cholesterol. Error bars represent the standard deviation. Statistical analyses were done with one-way ANOVA (Donnett
post test). *p < 0.05 versus WD.
(D) Effect of lovastatin and betulin on fecal triglyceride levels (TG). Error bars represent the standard deviation. Statistical analyses were done with one-way
ANOVA (Donnett post test). *p < 0.05 versus WD.
(E) Physical activity was recorded. Error bars represent the standard deviation.
(F) Respiratory quotient (RQ) of different groups was recorded. Error bars represent the standard deviation. Statistical analyses were done with one-way ANOVA
(Donnett post test). *p < 0.05 versus WD.
(G) VO2 (volume of oxygen consumed) of different groups was recorded. Error bars represent the standard deviation. Statistical analyses were done with one-way
ANOVA (Donnett post test). *p < 0.05 versus WD.
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pathway can be a potential therapeutic target to treat metabolic
diseases, especially type II diabetes and atherosclerosis.
In past decades, the lab of Brown and Goldstein has delin-
eated the SREBP pathway (Goldstein et al., 2006; Brown and
Goldstein, 2009). Besides the sterol-regulated maturation of
SREBP, the n-SREBPs are rapidly degraded through SCFFbw7-
mediated ubiquitination (Sundqvist et al., 2005). The complexity
of this regulatory pathway for SREBP indicates that different
strategies could be developed to inactivate it—for example,
stimulating the interaction between SCAP and Insig, inhibiting
the S1P or S2P, and accelerating the degradation of n-SREBPs.
Here, we employed a cell-based reporter assay with a functional
readout, which can be used to identify SREBP inhibitors or acti-
vators working on any of these steps. The finding of betulin vali-
dates our assay. Interestingly, betulin works through stimulating
SCAP-Insig association, the step that endogenous regulators of
SREBP including cholesterol and oxysterols regulate. It has been
shown that SREBP-2 transport is blocked in cultured cells when
ER cholesterol exceeds 5% of total ER lipids (molar basis) (Rad-
hakrishnan et al., 2008). It is interesting to test the concentration
of cholesterol in ER after betulin treatment.
25-HC is one of the most potent small-molecule compounds
that inhibit SREBP cleavage. Its potency is >100-fold higher
than that of cholesterol. Here, we identified betulin, which
inhibits the maturation of n-SREBP with the similar potency of
25-HC in cellular assays (Figure 1). Moreover, it does not acti-
vate LXR or promote the degradation of HMGCR (Figure 1).
The potency and specificity of betulin ensure the decrease of
both cholesterol and fatty acid, and therefore significantly
improves the pathological parameters of atherosclerosis and
type II diabetes in vivo.
Statins are the most widely prescribed drugs to treat hyper-
cholesterolemia. As an inhibitor of HMGCR, statin blocks choles-
terol biosynthesis. Meanwhile, inhibition of cholesterol synthesis
in liver stimulates SREBP, upregulates LDLR, and increases LDL
uptake (Goldstein and Brown, 2009). Through these two mecha-
nisms, statin effectively reduces the serum cholesterol level.
However, statin activates SREBP and raises liver cholesterol
and fatty acid biosynthetic enzymes, which lead to adverse
effects (Kita et al., 1980; Singer et al., 1984). On the other
hand, betulin directly inhibits SREBP and downregulates choles-
terol and fatty acid synthesis (Figure 3). Whenmice were fed with
equal amount of lovastatin or betulin, betulin showed similar or
even better beneficial effects; for instance, betulin decreased
lipid level to a greater extent than lovastatin in liver, WAT, and
BAT (Figure 5). And betulin showed a better effect than lovastatin
in improving insulin sensitivity (Figure 6 and Figure S3), since it
also decreases fatty acid and TG synthesis besides inhibiting
cholesterol synthesis (Figure 3).(H) Energy expenditure (EE) was calculated with the equation of Weir, EE (Kcal/kg
ation. Statistical analyses were done with one-way ANOVA (Donnett post test). *
(I) Body temperature of different groups of mice at different times after cold expos
done with repeated-measures two-way ANOVA (Bonferroni post test). **p < 0.01
(J) Gene expression of different groups of mice in brown adipose tissue (BAT) det
the amount of mRNA relative to that in mice fed onWD in each experiment, which i
analyses were done with one-way ANOVA (Donnett post test). **p < 0.01 versus
See also Figure S2.
CIn conclusion, we have identified a specific small-molecule
inhibitor of SREBP, betulin, which decreases lipid levels,
enhances insulin sensitivity, and reduces the development of
atherosclerotic plaques. These data support the notion that
inhibition of SREBP pathway may be a useful strategy to treat
type II diabetes and atherosclerosis. Betulin can serve as a
leading compound for pharmacological control of metabolic
diseases.
EXPERIMENTAL PROCEDURES
A complete description of materials and other methods is available in the
Supplemental Experimental Procedures.
Generation of Huh-7/SRE-Luc and Compound Screening
Huh-7 cells were transfected with pSRE-Luciferase and pEGFP-N1 (Invitro-
gen) with the ratio of 5:1. Forty-eight hours later, cells were switched to
medium A supplemented with 10% FBS and 700 mg/ml G418. Fresh medium
was exchanged every 2–3 days until colonies formed after about 2 weeks. Indi-
vidual colonieswere isolatedwith cloning cylinders and the resulting clone was
named Huh-7/SRE-Luc.
Huh-7/SRE-Luc cells were depleted of sterols by incubatin for 16 hr in
medium containing lipoprotein deficient serum (LPDS), the HMGCR inhibitor
compactin, and a low level of mevalonate (50 mM) that assures viability. The
sterol-depletion treatment will induce the maximal activity of SREBP.
Then cells were incubated individually with compounds at concentrations of
0.5–5 mM in 96-well plates. The luciferase activity was measured after 6 hr
treatment and the intensity of EGFPwas also measured as the internal control.
Click Chemistry
This reaction was performed as previous reports (Qiu et al., 2006). In brief, the
complementary tag biotin-alkyne (10 mM, final concentration) was added to the
mixture, and then ascorbate sodium (10 mM, final concentration) was added.
The mixture was gently mixed, and CuSO4 (1 mM, final concentration) was
added in. The mixture was mixed again and allowed to react at room temper-
ature for 1 hr.
Analysis of De Novo Synthesis of Lipid
Cells were incubated in medium A containing 10% dilipid-FCS, 1 mM lova-
statin, and 50 mM mevalonate supplemented with increasing concentrations
of betulin or 1 mM of lovastatin for 16 hr. [14C]acetate (12 mCi/60 mm dish)
was directly added in and incubated for additional 2 hr. The cells were
washed and dissolved with 0.1 N NaOH, and cell suspensions were auto-
claved for alkaline saponification. Then the nonpolar lipids (cholesterol)
were extracted in petroleum ether and evaporated to dryness with N2. After
addition of concentrated HCl, polar lipids (fatty acids) were extracted in petro-
leum ether and evaporated to dryness with N2. The lipids were resolved by
thin-layer chromatography (Silica gel 60, Merck). The radioactive products
were identified by comparison with unlabeled standards and visualized with
iodine vapor.
Filipin Staining and Nile-Red Staining
A fresh 5 mg/ml stock solution of filipin was prepared in ethanol and 0.5 mg/ml
stock solution of Nile-red was prepared in PBS. After fixation with 4% parafor-
maldehyde (PFA) in PBS, cells were washed twice with PBS and stained with
50 mg/ml filipin or 0.5 mg/ml Nile-red in the dark for 30 min at room temperature/hr) = (3.8183 VO2) + (1.2323 VCO2). Error bars represent the standard devi-
p < 0.05 versus WD.
ure (4C). Error bars represent the standard deviation. Statistical analyses were
WD+B versus WD.
ermined by Q-PCR. Mouse GAPDH was used as the control. Values represent
s arbitrarily defined as 1. Error bars represent the standard deviation. Statistical
WD.
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Figure 5. Effects of Betulin on Lipid Levels in Blood and Tissues
The mice used here are the same as those used in Figure 4. WD, western-type diet; L, lovastatin (30 mg/kg/day); B, betulin (15 or 30 mg/kg/day).
(A–D) Blood total cholesterol (TC) levels, triglyceride levels (TG), low-density lipoprotein cholesterol (LDL-c) levels, and high-density lipoprotein cholesterol
(HDL-c) levels after 6 week treatment. Error bars represent the standard deviation. Statistical analyses were done with one-way ANOVA (Donnett post test).
*p < 0.05, **p < 0.01 versus WD.
(E and F) TC and TG levels in liver after 6 week treatment. Error bars represent the standard deviation. Statistical analyses were done with one-way ANOVA
(Donnett post test). *p < 0.05 versus WD.
(G) Histological analysis of liver, white adipose tissue (WAT), and brown adipose tissue (BAT) after 6 week treatment. Liver tissues were stained with oil red O to
visualize lipid contents and counterstained with hematoxylin. WAT and BAT were stained with hematoxylin and eosin. Scale bars represent 100 mm.
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were analyzed with a Zeiss LSM 510 confocal microscope equipped with
a two-photon laser using an excitatory wavelength of 720 nm. Red pseudo-
color was assigned to show the filipin or Nile-red signal. In each experiment,
images were acquired at identical laser output, gain, and offset.52 Cell Metabolism 13, 44–56, January 5, 2011 ª2011 Elsevier Inc.Fluorescence Quantification
For quantification of intracellular cholesterol and fatty acid abundance, red
pseudocolors that showed the filipin or Nile-Red signal were measured by
Image-Pro Plus 5.02 and calculated. The intensity of control cell was arbitrarily
defined as 1, against which the intensities of different treated cells were
Figure 6. Effects of Betulin on Diet-Induced
Glucose Intolerance and Insulin Resistance
in Mice
Male C57BL/6J mice at 6 weeks of age were
randomly grouped (five to six per group). Mice
were allowed ad libitum access to water and
different types of diets. Vehicle, 30 mg/kg/day of
lovastatin, or betulin was administrated to mice
by gastric irrigation once daily. After 6 week treat-
ment, the mice were subjected to different tests as
indicated below. WD, western-type diet; L, lova-
statin; B, betulin.
(A) Effect of betulin on glucose tolerance in WD-
fed mice as determined by glucose tolerance
test (GTT).
(B) Quantification of the area under the curve
(AUC) from the GTT in (A). Error bars represent
the standard deviation. Statistical analyses were
done with one-way ANOVA (Donnett post test).
*p < 0.05 versus WD.
(C) Effect of betulin on insulin resistance inWD-fed
mice determined by insulin tolerance test (ITT).
(D) Quantification of the AUC of the ITT in (C). Error
bars represent the standard deviation. Statistical
analyses were done with one-way ANOVA (Don-
nett post test). *p < 0.05 versus WD.
(E and F) Blood glucose (E) and blood insulin (F) in
WD-fed mice were improved by betulin treatment.
Error bars represent the standard deviation.
Statistical analyses were done with one-way
ANOVA (Donnett post test). *p < 0.05 versus WD.
See also Figure S3.
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lated. The data shown in the figures are representative of three independent
experiments.
Animals and Treatment
All animals were maintained and used in accordance with the guidelines of the
Institutional Animal Care andUseCommittee of the Shanghai Institutes for Bio-
logical Sciences. Mice were treated as described in figure legends. WD was
normal chow supplemented with 1.25% cholesterol, 20% fat, and 0.5% cholic
acid w/w. HF was research diet, 34.9% w/w).
Metabolic Measurements
After receiving different treatments for 6 weeks, mice from each group
were acclimated in a comprehensive lab animal monitoring system (Columbus
Instruments, Columbus, OH) for 24 hr according to the instructions of the
manufacturer. After mice adapted to the metabolic chamber, volume of O2
consumption and CO2 production were continuously recorded over a 24 hr
period. RQ equals volumes of CO2 released/volumes of O2 consumed.
Rectal Temperature Measurement
The rectal temperatures of the mice were measured with a rectal probe
attached to a digital thermometer (Physitemp., NJ).Cell Metabolism 13, 44–Fecal Cholesterol and Triglyceride
Measurements
Fecal samples were collected over the final 3 days
of the study and freeze dried (lyophilized) and
ground up prior to analysis. Dry feces (250 mg)
were extracted with 4 ml of methanol:chloroform
(1:2, vol/vol) twice. The supernatants were pooled.
Exactly 100 ml was removed and evaporated to
dryness. Triglyceride was measured with WAKOkit. Then other 4 ml supernatants of 5 N KOH:ethanol (10:90 by volume)
were added to each 4 ml sample, capped, and heated at 70C for 1 hr. After
cooling to room temperature, 2 ml distilled water was added and saturated
with sodium chloride, followed by solvent extraction with 3 ml hexane twice.
The hexane extraction was repeated two more times and pooled. The hexane
extracts were dried and redissolved with 50 ml hexane. To the hexane portion,
50 ml 5-a-cholestane (1 mg/ml) was added. Then 1 ml was injected and
analyzed by GC-MS.
Gas Chromatography-Mass Spectrometry Analyses
GC-MS analyses were performed with an Agilent 7890A gas chromatograph
interfaced to an Agilent 5975C mass-selective detector and equipped with
an HP-5 (5% phenyl-95% methylpolysiloxane bonded phase; 30 m 3
0.25mm inner diameter, 0.25 mmfilm thickness) column (Agilent Technologies,
USA). The temperatures of the injector, interface, and ion source were 260C,
300C, and 230C, respectively. Helium was used as the carrier gas at a flow
rate of 0.5 ml/min in constant flow mode.
Serum and Liver Lipid Determination
Serum total cholesterol and triglyceride levels were enzymatically measured
with the kit (Wako, Japan), and low-density and high-density lipoprotein
cholesterol levels were determined according to the manufacturer’s instruc-
tions (Applygen, China). Liver tissues were homogenized and centrifuged.56, January 5, 2011 ª2011 Elsevier Inc. 53
Figure 7. Treatment of Betulin Decreases Atherosclerosis in LDLR–/– Mice
Eight-week-old male LDLR/mice were randomly grouped and fed with WD supplemented with vehicle (n = 7), 30 mg/kg/day of lovastatin (n = 3), or 30 mg/kg/
day of betulin (n = 6) for 14 weeks. Blood samples were collected 3 days before the end of treatment and centrifugalized for serum. At the end of experiment, the
aorta and liver were isolated for further analysis. WD, western-type diet; L, lovastatin; B, betulin.
(A) Consumption of western-type diet of LDLR/ mice.
(B) Average body weight of LDLR/ mice after 14 week treatment.
(C) Q-PCR anlysis of gene expression in LDLR/mice liver after 14 week treatment. RNA from livers was prepared. For each group, equal amounts of total RNA
from three to seven mice were subjected to Q-PCR quantification as described in the Experimental Procedures. MouseGAPDHwas used as the control. Values
represent the amount of mRNA relative to that in mice fed onWD in each experiment, which is arbitrarily defined as 1. Error bars represent the standard deviation.
Statistical analyses were done with one-way ANOVA (Donnett post test). *p < 0.05, **p < 0.01, ***p < 0.001 versus WD.
(D–G) Levels of TC, TG, LDL-c, and HDL-c in blood after 14 week treatment were shown. Error bars represent the standard deviation. Statistical analyses were
done with one-way ANOVA (Donnett post test). *p < 0.05 versus WD.
(H) Representative photographs from en face analysis of aortas from different groups after 14 week treatment.
(I–L) Quantifications of the lesion areas in (H). Error bars represent the standard deviation. Statistical analyses were done with one-way ANOVA (Donnett post
test). *p < 0.05, **p < 0.01 versus WD.
See also Figure S7.
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determined.
Histological Analysis of Liver and Adipose
For microscopic analysis of lipid accumulation in liver, tissues were embedded
in Tissue-Tek OCT cryostat molds (Leica) and frozen at 80C. These tissues
were used to generate 10-mm-thick sections in a cryostat. Tissue sections
were stained in 0.5% oil red O and counterstained with Mayer’s hematoxylin
for 1 min. Adipose tissues were embedded in paraffin and sectioned at 5 mm
onto poly-L-lysine-coated slides. For histology, sections were stained with
hematoxylin and eosin.
Glucose Tolerance and Insulin Tolerance Tests
Glucose tolerance and insulin tolerance tests were performed on mice fasted
overnight. Mice were injected with either 2 g/kg glucose or 0.75 U/kg insulin
(Sigma) into the peritoneal cavity. Glucose levels were measured from tail
blood before and 15, 30, 60, or 120 min after the injection with the Onetouch
Ultra blood glucose monitoring system (LifeScan). All animals were sacrificed
3 days after glucose tolerance or insulin tolerance tests, and blood and liver
were harvested. Plasma insulin levels were measured with the Mouse Insulin
Elisa kit (USCNLIFE) according to the manufacturer’s instructions.
Analysis of Atherosclerotic Lesions
To quantify atherosclerosis along the entire aorta, the aortic tree was dissected
out and the lesions were stained with Sudan IV for 6 min, destained with 80%
ethanol for 3 min. Sudanophilic lesions were assessed by computer-assisted
image analysis. For microscopic analysis of atherosclerotic lesions in the prox-
imal aortic root, and the heart and 1 mm of the thoracic aorta were removed,
embedded in Tissue-Tek OCT cryostat molds, and frozen at 80C. These
tissues were used to generate 10-mm-thick cross-sections of the proximal
aorta. Tissue sections were stained in oil red O for 20 min and counterstained
with Mayer’s hematoxylin for 1 min. So that the detail composition of the pla-
que could be examined, immunofluorescence staining of macrophages and
smooth muscle cells were performed. Five sections from every mouse were
selected and stained for macrophages and smooth muscle cells with
MOMA-2 and a-actin, respectively. The lesions in aortic cross-sections were
quantified by computer-assisted morphometric analysis.
SUPPLEMENTAL INFORMATION
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